Free Trial
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free EDT Stock Alerts

Spectral Medical (EDT) Competitors

Spectral Medical logo
C$1.43 +0.01 (+0.70%)
As of 05/25/2026 03:40 PM Eastern
Compare

EDT vs. AKU, GEN, LMD, LXG, and SQD

Should you buy Spectral Medical stock or one of its competitors? MarketBeat compares Spectral Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spectral Medical include Akumin (AKU), GeneNews (GEN), LED Medical Diagnostics (LMD), LexaGene (LXG), and SQI Diagnostics (SQD). These companies are all part of the "diagnostics & research" industry.

How does Spectral Medical compare to Akumin?

Spectral Medical (TSE:EDT) and Akumin (TSE:AKU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Spectral Medical had 1 more articles in the media than Akumin. MarketBeat recorded 1 mentions for Spectral Medical and 0 mentions for Akumin. Spectral Medical's average media sentiment score of 0.67 beat Akumin's score of 0.00 indicating that Spectral Medical is being referred to more favorably in the media.

Company Overall Sentiment
Spectral Medical Positive
Akumin Neutral

0.0% of Spectral Medical shares are owned by institutional investors. Comparatively, 30.3% of Akumin shares are owned by institutional investors. 18.2% of Spectral Medical shares are owned by insiders. Comparatively, 33.0% of Akumin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Spectral Medical has a net margin of 0.00% compared to Akumin's net margin of -34.67%. Akumin's return on equity of -483.86% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Spectral MedicalN/A -973.97% -93.22%
Akumin -34.67%-483.86%0.47%

Spectral Medical has a beta of 0.647419, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Akumin has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

Spectral Medical has higher earnings, but lower revenue than Akumin. Spectral Medical is trading at a lower price-to-earnings ratio than Akumin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectral MedicalC$2.76M151.97-C$18.68M-C$0.13N/A
AkuminC$737.69M0.00-C$255.80M-C$3.80N/A

Summary

Spectral Medical and Akumin tied by winning 6 of the 12 factors compared between the two stocks.

How does Spectral Medical compare to GeneNews?

GeneNews (TSE:GEN) and Spectral Medical (TSE:EDT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

GeneNews' return on equity of 0.00% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
GeneNewsN/A N/A N/A
Spectral Medical N/A -973.97%-93.22%

0.0% of Spectral Medical shares are held by institutional investors. 18.2% of Spectral Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GeneNews has higher earnings, but lower revenue than Spectral Medical. Spectral Medical is trading at a lower price-to-earnings ratio than GeneNews, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GeneNewsC$234.59K0.00-C$11.56M-C$0.07N/A
Spectral MedicalC$2.76M151.97-C$18.68M-C$0.13N/A

In the previous week, Spectral Medical had 1 more articles in the media than GeneNews. MarketBeat recorded 1 mentions for Spectral Medical and 0 mentions for GeneNews. Spectral Medical's average media sentiment score of 0.67 beat GeneNews' score of 0.00 indicating that Spectral Medical is being referred to more favorably in the news media.

Company Overall Sentiment
GeneNews Neutral
Spectral Medical Positive

Summary

GeneNews and Spectral Medical tied by winning 5 of the 10 factors compared between the two stocks.

How does Spectral Medical compare to LED Medical Diagnostics?

Spectral Medical (TSE:EDT) and LED Medical Diagnostics (CVE:LMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

LED Medical Diagnostics has higher revenue and earnings than Spectral Medical. Spectral Medical is trading at a lower price-to-earnings ratio than LED Medical Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectral MedicalC$2.76M151.97-C$18.68M-C$0.13N/A
LED Medical DiagnosticsC$14.96M1.04-C$1.51M-C$0.04N/A

0.0% of Spectral Medical shares are held by institutional investors. 18.2% of Spectral Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

LED Medical Diagnostics' return on equity of 0.00% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Spectral MedicalN/A -973.97% -93.22%
LED Medical Diagnostics N/A N/A N/A

In the previous week, Spectral Medical had 1 more articles in the media than LED Medical Diagnostics. MarketBeat recorded 1 mentions for Spectral Medical and 0 mentions for LED Medical Diagnostics. Spectral Medical's average media sentiment score of 0.67 beat LED Medical Diagnostics' score of 0.00 indicating that Spectral Medical is being referred to more favorably in the media.

Company Overall Sentiment
Spectral Medical Positive
LED Medical Diagnostics Neutral

Summary

LED Medical Diagnostics beats Spectral Medical on 6 of the 11 factors compared between the two stocks.

How does Spectral Medical compare to LexaGene?

LexaGene (CVE:LXG) and Spectral Medical (TSE:EDT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

In the previous week, Spectral Medical had 1 more articles in the media than LexaGene. MarketBeat recorded 1 mentions for Spectral Medical and 0 mentions for LexaGene. Spectral Medical's average media sentiment score of 0.67 beat LexaGene's score of 0.00 indicating that Spectral Medical is being referred to more favorably in the news media.

Company Overall Sentiment
LexaGene Neutral
Spectral Medical Positive

LexaGene has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market. Comparatively, Spectral Medical has a beta of 0.647419, meaning that its share price is 35% less volatile than the broader market.

LexaGene's return on equity of -339.54% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
LexaGeneN/A -339.54% -120.21%
Spectral Medical N/A -973.97%-93.22%

0.1% of LexaGene shares are owned by institutional investors. Comparatively, 0.0% of Spectral Medical shares are owned by institutional investors. 17.9% of LexaGene shares are owned by insiders. Comparatively, 18.2% of Spectral Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

LexaGene has higher earnings, but lower revenue than Spectral Medical. Spectral Medical is trading at a lower price-to-earnings ratio than LexaGene, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LexaGeneC$110.93K133.13-C$8.54M-C$0.08N/A
Spectral MedicalC$2.76M151.97-C$18.68M-C$0.13N/A

Summary

LexaGene and Spectral Medical tied by winning 6 of the 12 factors compared between the two stocks.

How does Spectral Medical compare to SQI Diagnostics?

Spectral Medical (TSE:EDT) and SQI Diagnostics (CVE:SQD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Spectral Medical had 1 more articles in the media than SQI Diagnostics. MarketBeat recorded 1 mentions for Spectral Medical and 0 mentions for SQI Diagnostics. Spectral Medical's average media sentiment score of 0.67 beat SQI Diagnostics' score of 0.00 indicating that Spectral Medical is being referred to more favorably in the media.

Company Overall Sentiment
Spectral Medical Positive
SQI Diagnostics Neutral

0.0% of Spectral Medical shares are held by institutional investors. Comparatively, 25.2% of SQI Diagnostics shares are held by institutional investors. 18.2% of Spectral Medical shares are held by insiders. Comparatively, 50.2% of SQI Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spectral Medical has a beta of 0.647419, meaning that its share price is 35% less volatile than the broader market. Comparatively, SQI Diagnostics has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

SQI Diagnostics' return on equity of 0.00% beat Spectral Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Spectral MedicalN/A -973.97% -93.22%
SQI Diagnostics N/A N/A -74.70%

Spectral Medical has higher earnings, but lower revenue than SQI Diagnostics. Spectral Medical is trading at a lower price-to-earnings ratio than SQI Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spectral MedicalC$2.76M151.97-C$18.68M-C$0.13N/A
SQI DiagnosticsC$3.04M2.01-C$19.14M-C$0.05N/A

Summary

SQI Diagnostics beats Spectral Medical on 7 of the 12 factors compared between the two stocks.

Get Spectral Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDT vs. The Competition

Export
MetricSpectral MedicalDiagnostics & Research IndustryMedical SectorTSE Exchange
Market CapC$419.59MC$44.04MC$6.46BC$12.16B
Dividend Yield1.45%3.35%2.76%6.20%
P/E Ratio-11.000.7921.0037.64
Price / Sales151.97620.12558.1911.68
Price / Cash82.5011.4243.4982.29
Price / Book-17.883.4610.404.50
Net Income-C$18.68MC$334.07BC$3.57BC$299.09M
7 Day Performance4.38%-1.48%6.40%2.48%
1 Month Performance2.14%-2.75%3.55%1.47%
1 Year Performance70.24%10.11%34.13%53.55%

Spectral Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDT
Spectral Medical
N/AC$1.43
+0.7%		N/A+72.3%C$419.59MC$2.76MN/A29
AKU
Akumin
N/AN/AN/AN/AC$37.20MC$737.69MN/A1,527
GEN
GeneNews
N/AN/AN/AN/AC$25.49MC$234.59KN/A2,700
LMD
LED Medical Diagnostics
N/AC$0.40
+∞		N/A+0.0%C$15.51MC$14.96MN/A46
LXG
LexaGene
N/AC$0.11
-19.2%		N/A+0.0%C$14.77MC$110.93KN/A41

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:EDT) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel